← All Sponsors
SPONSOR

Nuvig Therapeutics, Inc.

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Chronic Inflammatory Demyelinating Polyneuropathy
NCT07027111 Phase 2
Recruiting

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Chronic Inflammatory Demyelinating Polyneuropathy
United States View Trial →